LunaRx Review: Pricing, Process, and Who It's For
An honest, structured look at LunaRx's compounded GLP-1 program — how the care model works, how pricing works, and what to verify before you start.

Disclosure
The GLP Journal is published by LunaRx. This review is written with that conflict of interest disclosed openly. We believe transparency beats pretending independence. This is not medical advice. Compounded GLP-1s are prepared by licensed 503A and 503B compounding pharmacies.
Because we publish this review and LunaRx, we'll be direct about what we're evaluating and why. LunaRx is a telehealth brand for GLP-1 weight care. Clinical services and fulfillment run through a third-party partner network rather than in-house, and the medication dispensed is compounded semaglutide or tirzepatide prepared by licensed 503A and 503B compounding pharmacies rather than the branded manufacturers. The useful thing to check is which pharmacies fill those prescriptions and whether they are properly licensed, so read the regulatory section below before the pricing section.
One structural point up front: compounding compliance is the pharmacy's responsibility. The 503A pharmacy or 503B outsourcing facility that prepares and ships the medication is the licensed party accountable for the compounding rules — not the telehealth brand that runs the intake and connects you to a prescriber. So the useful questions about LunaRx are which pharmacies fill its prescriptions and whether they are properly licensed, which you can ask directly.
| LunaRx | |
|---|---|
| Focus | Recomposition — lose fat, keep muscle |
| Care model | Physician-directed telehealth; the clinician approves or denies |
| Medications | Compounded semaglutide or tirzepatide |
| Muscle protection | Muscle-protective peptides built into the stack |
| Coming-off plan | Structured off-ramp / taper |
| Pricing | Flat, dose-independent — $139/mo semaglutide, $149/mo tirzepatide |
| If not approved | $0 — you only pay if a physician approves |
| Consultation | Live or store-and-forward, depending on your state |
| Languages | English and Spanish |
| Supply | Compounded, via licensed 503A and 503B pharmacies |
How does the LunaRx care model work?
The flow is standard telehealth, and you're in the driver's seat. You complete an intake questionnaire and indicate the treatment you're interested in. Depending on your state, you then have either a live (synchronous) consultation or a store-and-forward (asynchronous) review. A licensed physician reviews your intake and independently decides whether to prescribe — they can and do decline. If approved, a licensed pharmacy dispenses and ships to you.
Two things follow from that structure. The clinician is not a LunaRx employee making a sales decision, which is the point of the separation. But it also means LunaRx does not control the clinical call, so ask the prescriber your clinical questions directly rather than asking support. The stated differentiator is a 'come off clean' focus — the service frames GLP-1s as a tool with an exit, not a lifelong subscription.
What's included in a LunaRx plan?
LunaRx positions its plans as a full recomposition toolkit rather than a mailed vial. A plan generally includes the GLP-1 medication (compounded semaglutide or tirzepatide), muscle-protective peptides, physician-directed dosing with titration as you go, a structured off-ramp for coming off, and discreet, tracked delivery with no reconstitution required. Confirm exactly what your plan includes on the eligibility page before you start.
Does LunaRx protect muscle?
This is the core of the LunaRx pitch. A real share of the weight lost on a GLP-1 alone can be lean muscle, so LunaRx pairs the medication with muscle-protective peptides and protein-forward, resistance-first guidance. The stated goal is recomposition — losing fat while defending muscle — rather than just a lower number on the scale. If keeping strength and metabolic rate matters to you, this is the differentiator to weigh.
What about coming off? The off-ramp
Most platforms are built around the ongoing refill. LunaRx builds in an exit: a structured taper paired with GI-recovery and metabolic-reset support so you can come off without the rebound that tends to follow an abrupt stop. Its six-month blueprint runs intensive recomposition first, then steps the dose down in the final stretch. If 'how do I eventually get off this' is on your mind, it's a first-class part of the model.
Care in English and Spanish
LunaRx delivers care in English and Spanish — intake, the physician consultation, and support — which is worth noting because Spanish-speaking patients are underserved by most telehealth. If you'd rather do your intake and talk to your provider in Spanish, that option is built in.
How much does LunaRx cost?
LunaRx uses flat, dose-independent pricing — the monthly price stays the same no matter your dose, so it does not climb as you titrate up. As of 2026 that is $139/month for semaglutide and $149/month for tirzepatide. That structure is worth noting: many programs charge more as your dose increases, so a rate that holds steady is a real cost advantage for anyone who expects to move up. There's also $0 charge if you're not approved. Confirm the current price on the eligibility page, and ask what is included — shipping, follow-up, and any add-ons.
What are the tradeoffs with LunaRx?
- Pros: clinician-led model; muscle-protective peptides built in; explicit coming-off support; flat, dose-independent pricing that does not rise as you titrate up; $0 if you're not approved; care in English and Spanish; transparent about being a LunaRx publication.
- Cons to verify: the medication is compounded rather than the branded product, so it was not the exact formulation studied in the trials cited on this site — ask which licensed pharmacy prepares it and what that means for you. Confirm exactly what the flat price includes (shipping, follow-up, any add-ons) so you are comparing like for like. And like all telehealth, it is remote, which is not a substitute for in-person care when you need it.
Who is LunaRx a good fit for?
People who want a GLP-1 with a clinician in the loop, muscle protection built in, a clear path to taper, flat pricing that will not rise as their dose does, and the option of care in Spanish. If you need in-person monitoring or have complex comorbidities, talk to your primary clinician first.
Want this handled for you?
LunaRx — clinician-led GLP-1 care with a plan to come off
LunaRx connects you with a licensed clinician for an online evaluation. Depending on your state that is a live or a store-and-forward visit. If the clinician determines a GLP-1 is appropriate for you, a licensed pharmacy dispenses it — with a plan to come off when you’re ready. The prescribing decision is the clinician’s alone, and approval is not guaranteed.
Common questions about LunaRx
- How does LunaRx work?
- It is standard telehealth. You complete an intake questionnaire and indicate the treatment you're interested in, then have a live or store-and-forward consultation depending on your state. A licensed physician independently decides whether to prescribe and can decline. If approved, a licensed pharmacy dispenses and ships the medication.
- Does LunaRx sell compounded or brand GLP-1s?
- Compounded semaglutide or tirzepatide, prepared by licensed 503A and 503B compounding pharmacies. Ask which pharmacy fills your prescription and whether it is properly licensed.
- Does LunaRx help protect muscle?
- Yes — that's the core of its model. LunaRx pairs the GLP-1 with muscle-protective peptides and protein-forward, resistance-first guidance so more of what you lose is fat rather than lean muscle.
- Does LunaRx help you come off the medication?
- Yes. A structured off-ramp is central to the model: a taper paired with GI-recovery and metabolic-reset support, designed to help you come off without rebound weight gain.
- Does LunaRx offer care in Spanish?
- Yes. Intake, the physician consultation, and support are available in English and Spanish.
- How much does LunaRx cost?
- LunaRx uses flat, dose-independent pricing: the monthly cost stays the same no matter your dose, rather than rising as you titrate up. As of 2026 that is about $139/month for semaglutide and $149/month for tirzepatide, with $0 charge if you're not approved. Confirm the current price and what is included on the eligibility page.
- Who is responsible for compounding compliance at LunaRx?
- The dispensing pharmacy. The 503A pharmacy or 503B outsourcing facility that prepares and ships the medication is the licensed party accountable for the compounding rules, not the telehealth brand that runs the intake and connects you to a prescriber.
Bottom line
LunaRx is a telehealth GLP-1 service with a clinician-led model, muscle-protective peptides, a structured off-ramp, flat pricing, and care in English and Spanish. It uses compounded supply prepared by licensed 503A and 503B compounding pharmacies, so ask which pharmacy fills your prescription and whether it is properly licensed. We disclose that we publish this review. This is not a recommendation; it is information, and you should verify pricing, supply, and fit for your situation.
Sources
Primary sources for the claims in this article. Trial results are reported as published; prescribing information is the authoritative reference for dosing and safety.
- 1.FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
U.S. Food and Drug Administration · 2025
Shortages resolved (tirzepatide December 2024, semaglutide February 2025) and the compounding enforcement deadlines that followed.
- 2.Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A
U.S. Food and Drug Administration, guidance for industry · 2018
A 503A pharmacy may not compound, regularly or in inordinate amounts, a drug that is essentially a copy of a commercially available product. Patient-specific compounding remains possible where the prescriber documents a clinically significant difference for that patient.
- 3.FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
U.S. Food and Drug Administration · 2026
April 2026 proposal to exclude these molecules from the 503B bulk drug substances list.
Get the weekly research update
New trials, FDA moves, and pricing shifts — one plain-English email a week. No spam.
Unsubscribe anytime. Read our privacy policy.